Janux Therapeutics

JANXPhase 1

San Diego, United StatesFounded 2017januxrx.com

Janux Therapeutics is pioneering a new class of tumor-activated immunotherapies designed to overcome the limitations of traditional T-cell engagers, particularly their severe on-target, off-tumor toxicities. The company's proprietary platforms conditionally activate only in the tumor microenvironment, aiming to unlock the potential of powerful immunotherapies for solid tumors. With its lead candidate JANX007 in Phase 1 clinical trials for metastatic castration-resistant prostate cancer and a strong pipeline of other candidates, Janux is positioned at the forefront of next-generation immuno-oncology. The company went public in 2021 and is backed by a seasoned leadership team with deep experience in oncology drug development.

Market Cap

$855.3M

Founded

2017

Employees

50-100

Focus

Biotech

JANX · Stock Price

USD 14.060.45 (-3.10%)

Historical price data

AI Company Overview

Technology Platform

Proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms that use protease-sensitive masking to conditionally activate therapeutics only in the tumor microenvironment, aiming to enhance safety and efficacy.

Pipeline Snapshot

3 drugs in pipeline

Drug	Indication	Stage
JANX007 + Darolutamide	Prostate Cancer	Phase 1
JANX011	Autoimmune	Phase 1
JANX008	Non-Small Cell Lung Cancer	Phase 1

Funding History

Total raised: $256M

IPO$200MUndisclosedJul 28, 2021

Series A$56MRA Capital ManagementOct 15, 2020

Opportunities

Janux's tumor-activated platform has the potential to unlock the vast solid tumor market for T-cell engagers, a modality previously limited by toxicity.

The modular nature of the technology allows for rapid expansion into new high-value oncology targets beyond PSMA and EGFR.

Successful clinical proof-of-concept could position the company as an attractive partner or acquisition target for large pharmaceutical firms.

Risk Factors

The company faces significant clinical risk, as its lead programs are in early-stage trials and the core platform technology of tumor-activated masking remains unproven in late-stage studies.

Intense competition in the immuno-oncology space from both large pharma and other innovative biotechs presents a constant challenge.

Manufacturing complexities and future commercialization hurdles are additional long-term risks.

Competitive Landscape

Janux competes in the crowded bispecific T-cell engager space against giants like Amgen and Roche, as well as other biotechs like Affimed and Harpoon. Its primary differentiation is the focus on protease-activated masking to improve safety. Key competitors in its specific target areas include Novartis' Pluvicto (PSMA-targeted radiopharmaceutical) and various EGFR-targeted therapies from multiple companies.

Publications

Patents

Pipeline